Home
Storia in 1 fonti
UBS downgrades Novo Nordisk, cites 'rapidly deteriorating growth' in GLP-1 market
Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
Raccontata da
cnbc.com
Timeline cronologica
- ·
UBS downgrades Novo Nordisk, cites 'rapidly deteriorating growth' in GLP-1 market
Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
- ·
'We are lowering our prices' in the U.S. says Novo Nordisk CFO
Karsten Munk Knudsen, CFO of Novo Nordisk, discusses the prospect of tariffs on pharmaceuticals and the importance of the U.S. market to the Danish drugmaker.